OSI 930
Alternative Names: OSI-930Latest Information Update: 16 Jul 2016
At a glance
- Originator OSI Pharmaceuticals
- Class Antineoplastics; Quinolines; Small molecules; Thiophenes
- Mechanism of Action Proto-oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in United Kingdom (PO, Tablet)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (PO, Tablet)
- 07 Oct 2010 OSI completes a phase I trial (NCT00513851) in late-stage Solid tumours in USA